Overview
- Embecta will pay £100 million in cash at closing and up to £50 million in performance-based payments tied to Aidaptus auto-injector sales over the three years after closing.
- The transaction won unanimous board approval and is targeted to close in Embecta’s fiscal third quarter of 2026, pending regulatory approvals and other customary conditions.
- Embecta plans to fund the purchase with borrowings under its revolving credit facility and says it remains committed to paying down debt over time.
- Owen Mumford, a UK-based, family-owned drug-delivery and medical device maker with a 70-year history, generated £69.4 million in fiscal 2025 revenue and pioneered the first plastic auto-injector.
- Embecta projects the deal will be immaterial to adjusted operating income in fiscal 2027 with accretion thereafter, aims for a high-single-digit ROIC by year four, and will discuss details on May 5, 2026.